Matrix metalloproteinase family gene polymorphisms and risk for coronary artery disease: Systematic review and meta-analysis

Heart

Volumn 98, Issue 20, 2012, Pages 1483-1491

  Niu, Wenquan ^a,b   Qi, Yue ^c,d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Institute of Hypertension   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GELATINASE A; GELATINASE B; GLUTAMIC ACID; GLUTAMINE; INTERSTITIAL COLLAGENASE; LYSINE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; STROMELYSIN;

ACUTE CORONARY SYNDROME; AMINO ACID SUBSTITUTION; ASIAN; CORONARY ARTERY DISEASE; CORONARY RISK; ETHNIC DIFFERENCE; GELATINASE A GENE; GELATINASE B GENE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART INFARCTION; HUMAN; INTERSTITIAL COLLAGENASE GENE; MACROPHAGE ELASTASE GENE; MATRIX METALLOPROTEINASE GENE; MULTIGENE FAMILY; PRIORITY JOURNAL; REVIEW; STROMELYSIN GENE; SYSTEMATIC REVIEW;

CORONARY ARTERY DISEASE; HUMANS; MATRIX METALLOPROTEINASES; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84866626281     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302085     Document Type: Review

References (70)

1. Rajavashisth TB, Xu XP, Jovinge S, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999;99:3103-9.
2. Johnson JL, Jackson CL, Angelini GD, et al. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1998;18:1707-15.
3. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
4. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899-904.
5. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-9.
6. Back M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010;52:410-28.
7. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003;59:812-23.
8. Beyzade S, Zhang S, Wong YK, et al. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 2003;41:2130-7.
9. Fallah S, Seifi M, Samadikuchaksaraei A. Risk of coronary artery stenosis in Iranian type 2 diabetics: is there a role for matrix metalloproteinase-3 gene (-1612 5A/6A) polymorphism? J Physiol Biochem 2010;66:359-64.
10. Koch W, de Waha A, Hoppmann P, et al. Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: case-control study and a meta-analysis. Atherosclerosis 2010;208:171-6.
11. Shioji K, Kokubo Y, Goto Y, et al. An association analysis between genetic polymorphisms of matrix metalloproteinase-3 and methylenetetrahydrofolate reductase and myocardial infarction in Japanese. J Thromb Haemost 2004;2:527-8.
12. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
13. Thakkinstian A, McEvoy M, Minelli C, et al. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 2005;162:201-11.
14. Bowden J, Tierney JF, Copas AJ, et al. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol 2011;11:41.
15. Alp E, Menevse S, Tulmac M, et al. Lack of association between matrix metalloproteinase-9 and endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population. DNA Cell Biol 2009;28:343-50.
16. Alp E, Menevse S, Tulmac M, et al. The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction. Genet Test Mol Biomark 2011;15:193-202.
17. Cho HJ, Chae IH, Park KW, et al. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet 2002;47:88-91.
18. Dalepiane VL, Silvello DN, Paludo CA, et al. Matrix metalloproteinase gene polymorphisms in patients with coronary artery disease. Genet Mol Biol 2007;30:505-10.
19. Delgado-Enciso I, Gonzalez-Hernandez NA, Baltazar-Rodriguez LM, et al. Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population. J Genet 2009;88:249-52.
20. Drzewoski J, Sliwinska A, Przybylowska K, et al. Gene polymorphisms and antigen levels of matrix metalloproteinase-1 in type 2 diabetes mellitus coexisting with coronary heart disease. Kardiol Pol 2008;66:1042-8.
21. Fallah S, Seifi M, Ghasemi A, et al. Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects. J Clin Lab Anal 2010;24:305-10.
22. Gao B, Li ZC. [Association between serum matrix metalloproteinase-3 concentration and the promoter 5A/6A polymorphism in patients with coronary heart disease]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004;16:536-9.
23. Ghaderian SM, Akbarzadeh Najar R, Tabatabaei Panah AS. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis 2010;21:330-5.
24. Haberbosch W, Gardemann A. Gelatinase B C(-1562)T polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest 2005;65:513-22.
25. Han Y, Wu Z, Zhang X, et al. Impact of matrix metalloproteinase-1 gene variations on risk of acute coronary syndrome. Coron Artery Dis 2008;19:227-30.
26. Han YL, Wu ZF, Zhang XL, et al. Matrix metalloproteinase-1 gene -519A/G polymorphism and the risk of coronary heart disease in Northern Chinese Han population. Zhonghua Xin Xue Guan Bing Za Zhi 2008;36:195-8.
27. Horne BD, Camp NJ, Carlquist JF, et al. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am Heart J 2007;154:751-8.
28. Hubacek JA, Stanek V, Gebauerova M, et al. Lack of an association between connexin-37, stromelysin-1, plasminogen activator-inhibitor type 1 and lymphotoxinalpha genes and acute coronary syndrome in Czech Caucasians. Exp Clin Cardiol 2010;15:e52-6.
29. Humphries SE, Martin S, Cooper J, et al. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002;66:343-52.
30. Jguirim-Souissi I, Jelassi A, Slimani A, et al. Matrix metalloproteinase-1 and matrix metalloproteinase-12 gene polymorphisms and the outcome of coronary artery disease. Coron Artery Dis 2011;22:388-93.
31. Kim JS, Park HY, Kwon JH, et al. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J 2002;43:473-81.
32. Lamblin N, Bauters C, Hermant X, et al. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 2002;40:43-8.
33. Liu PY, Chen JH, Li YH, et al. Synergistic effect of stromelysin-1 (matrix metalloproteinase- 3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003;90:132-9.
34. Liu PY, Li YH, Chan SH, et al. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol 2006;98:1012-17.
35. Morgan AR, Zhang B, Tapper W, et al. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med (Berl) 2003;81:321-6.
36. Morgan TM, Krumholz HM, Lifton RP, et al. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007;297:1551-61.
37. Nanni S, Melandri G, Hanemaaijer R, et al. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res 2007;149:137-44.
38. Nojiri T, Morita H, Imai Y, et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol 2003;92:181-6.
39. Nuzzo D, Vasto S, Balistreri CR, et al. Role of proinflammatory alleles in longevity and atherosclerosis: results of studies performed on -1562C/T MMP-9 in centenarians and myocardial infarction patients from Sicily. Ann N Y Acad Sci 2006;1089:496-501.
40. Ozkok E, Aydin M, Babalik E, et al. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Med Sci Monit 2008;14:CR536-42.
41. Pearce E, Tregouet DA, Samnegard A, et al. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ Res 2005;97:1070-6.
42. Qin Q, Zhao BR, Mao YM, et al. Association of matrix metalloproteinase-9 and platelet membrane glycoprotein VI polymorphisms with acute coronary syndrome. Zhonghua Xin Xue Guan Bing Za Zhi 2005;33:622-6.
43. Roman-Garcia P, Coto E, Reguero JR, et al. Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a case-control study in a Spanish population. Coron Artery Dis 2009;20:383-6.
44. Samnegard A, Silveira A, Lundman P, et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 2005;258:411-19.
45. Schwarz A, Haberbosch W, Tillmanns H, et al. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers 2002;18:121-8.
46. Seifi M, Fallah S, Firoozrai M. Influence of genetic polymorphism in matrix metalloproteinase-3 on extent of coronary atherosclerosis and risk of coronary artery stenosis. Arch Med Res 2009;40:600-4.
47. Tang LJ, Chen XF, Zhu M, et al. Study of relations between matrix metalloproteinase-9 polymorphism (C-1562T) and acute coronary syndrome in Han population of China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005;22:313-16.
48. Terashima M, Akita H, Kanazawa K, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999;99:2717-19.
49. Tobin MD, Braund PS, Burton PR, et al. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J 2004;25:459-67.
50. Vasku A, Goldbergova M, Izakovicova Holla L, et al. A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol 2004;22:585-91.
51. Wang J, Warzecha D, Wilcken D, et al. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci (Lond) 2001;101:87-92.
52. Wang L, Ma YT, Xie X, et al. Interaction between MMP-9 gene polymorphisms and smoking in relation to myocardial infarction in a Uighur population. Clin Appl Thromb Hemost 2012;18:72-8.
53. Wu N, Lu X, Hua Y, et al. Haplotype analysis of the stromelysin-1 (MMP3) and gelatinase B (MMP9) genes in relation to coronary heart disease. Ann Hum Genet 2009;73:404-10.
54. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002;347:1916-23.
55. Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J 2003;24:1668-71.
56. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-94.
57. Zhi H, Wang H, Ren L, et al. Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population. Mol Biol Rep 2010;37:13-20.
58. Zhou X, Huang J, Chen J, et al. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb Haemost 2004;92:867-73.
59. Anzai A, Anzai T, Nagai S, et al. Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling. Circulation 2012;125:1234-45.
60. Wang L, Ma YT, Xie X, et al. Interaction between MMP-9 gene polymorphisms and smoking in relation to myocardial infarction in a Uighur population. Clin Appl Thromb Hemost 2012;18:72-8.
61. Wang J, Xu D, Wu X, et al. Polymorphisms of matrix metalloproteinases in myocardial infarction: a meta-analysis. Heart 2011;97:1542-6.
62. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141:137-47.
63. Liu Y, Yang YM, Zhu J, et al. Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and metaanalysis. Cardiovasc Diabetol 2011;10:98.
64. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001;2:91-9.
65. Lindsey ML, Escobar GP, Dobrucki LW, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 2006;290:H232-9.
66. Opstad TB, Pettersen AA, Weiss TW, et al. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta 2012;413:113-20.
67. Tanindi A, Sahinarslan A, Elbeg S, et al. Relationship between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical Presentation, extent and severity of atherosclerotic coronary artery disease. Open Cardiovasc Med J 2011;5:110-16.
68. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-31.
69. Tang TT, Yuan J, Zhu ZF, et al. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res Cardiol 2012;107:232.
70. Zintzaras E, Raman G, Kitsios G, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a metaanalysis. Arch Intern Med 2008;168:1077-89.